Increased	increased	O	O	O	O
frequency	frequency	O	O	O	O
of	of	O	O	O	O
venous	venous	O	DISEASE	OTHERS	I
thromboembolism	thromboembolism	O	DISEASE	OTHERS	I
with	with	O	O	O	O
the	the	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
docetaxel	docetaxel	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
metastatic	metastatic	O	O	O	O
androgen-independent	androgen-independent	O	O	O	O
prostate	prostate	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
.	.	O	O	O	O

STUDY	study	O	O	O	O
OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
frequency	frequency	O	O	O	O
of	of	O	O	O	O
venous	venous	O	DISEASE	OTHERS	I
thromboembolism	thromboembolism	O	DISEASE	OTHERS	I
(	(	O	O	O	O
VTE	vte	O	DISEASE	OTHERS	I
)	)	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
advanced	advanced	O	O	O	O
androgen-independent	androgen-independent	O	O	O	O
prostate	prostate	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
who	who	O	O	O	O
were	were	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
docetaxel	docetaxel	CHEMICALS	O	OTHERS	I
alone	alone	O	O	O	O
or	or	O	O	O	O
in	in	O	O	O	O
combination	combination	O	O	O	O
with	with	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

DESIGN	design	O	O	O	O
:	:	O	O	O	O
Retrospective	retrospective	O	O	O	O
analysis	analysis	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
randomized	randomized	O	O	O	O
phase	phase	O	O	O	O
II	ii	O	O	O	O
trial	trial	O	O	O	O
.	.	O	O	O	O

SETTING	setting	O	O	O	O
:	:	O	O	O	O
National	national	O	O	O	O
Institutes	institutes	O	O	O	O
of	of	O	O	O	O
Health	health	O	O	O	O
clinical	clinical	O	O	O	O
research	research	O	O	O	O
center	center	O	O	O	O
.	.	O	O	O	O

PATIENTS	patients	O	O	O	O
:	:	O	O	O	O
Seventy	seventy	O	O	O	O
men	men	O	O	O	O
,	,	O	O	O	O
aged	aged	O	O	O	O
50	50	O	O	O	O
-	-	O	O	O	O
80	80	O	O	O	O
years	years	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
advanced	advanced	O	O	O	O
androgen-independent	androgen-independent	O	O	O	O
prostate	prostate	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
.	.	O	O	O	O

INTERVENTION	intervention	O	O	O	O
:	:	O	O	O	O
Each	each	O	O	O	O
patient	patient	O	O	O	O
received	received	O	O	O	O
either	either	O	O	O	O
intravenous	intravenous	O	O	O	O
docetaxel	docetaxel	CHEMICALS	O	OTHERS	I
30	30	O	O	O	O
mg/m2/week	mg/m2/week	O	O	O	O
for	for	O	O	O	O
3	3	O	O	O	O
consecutive	consecutive	O	O	O	O
weeks	weeks	O	O	O	O
,	,	O	O	O	O
followed	followed	O	O	O	O
by	by	O	O	O	O
1	1	O	O	O	O
week	week	O	O	O	O
off	off	O	O	O	O
,	,	O	O	O	O
or	or	O	O	O	O
the	the	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
continuous	continuous	O	O	O	O
oral	oral	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
200	200	O	O	O	O
mg	mg	O	O	OTHERS	I
every	every	O	O	O	O
evening	evening	O	O	O	O
plus	plus	O	O	O	O
the	the	O	O	O	O
same	same	O	O	O	O
docetaxel	docetaxel	CHEMICALS	O	OTHERS	I
regimen	regimen	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
4-week	4-week	O	O	O	O
cycle	cycle	O	O	O	O
was	was	O	O	O	O
repeated	repeated	O	O	O	O
until	until	O	O	O	O
there	there	O	O	O	O
was	was	O	O	O	O
evidence	evidence	O	O	O	O
of	of	O	O	O	O
excessive	excessive	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
or	or	O	O	O	O
disease	disease	O	DISEASE	OTHERS	I
progression	progression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

MEASUREMENTS	measurements	O	O	O	O
AND	and	O	O	O	O
MAIN	main	O	O	O	O
RESULTS	results	O	O	O	O
:	:	O	O	O	O
None	none	O	O	O	O
of	of	O	O	O	O
23	23	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
received	received	O	O	O	O
docetaxel	docetaxel	CHEMICALS	O	OTHERS	I
alone	alone	O	O	O	O
developed	developed	O	O	O	O
VTE	vte	O	DISEASE	OTHERS	I
,	,	O	O	O	O
whereas	whereas	O	O	O	O
9	9	O	O	O	O
of	of	O	O	O	O
47	47	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
19	19	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
who	who	O	O	O	O
received	received	O	O	O	O
docetaxel	docetaxel	CHEMICALS	O	OTHERS	I
plus	plus	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
developed	developed	O	O	O	O
VTE	vte	O	DISEASE	OTHERS	I
(	(	O	O	O	O
p=0.025	p=0.025	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
addition	addition	O	O	O	O
of	of	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
docetaxel	docetaxel	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
prostate	prostate	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
significantly	significantly	O	O	O	O
increases	increases	O	O	O	O
the	the	O	O	O	O
frequency	frequency	O	O	O	O
of	of	O	O	O	O
VTE	vte	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Clinicians	clinicians	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
aware	aware	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
potential	potential	O	O	O	O
complication	complication	O	O	O	O
when	when	O	O	O	O
adding	adding	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
chemotherapeutic	chemotherapeutic	O	O	O	O
regimens	regimens	O	O	O	O
.	.	O	O	O	O

